Anagnostou T, Litzow MR. Blood Lymphat Cancer. 2018;8:1–9.
On page 2, Table 1 was incorrectly presented. Table 1 should have been:
Table 1.
Inhibition of kinases by different TKIs approved for the treatment of CML and/or ALL
| Kinase | Imatinib | Dasatinib | Nilotinib | Bosutinib | Ponatinib |
|---|---|---|---|---|---|
| ABL1 | X | X | X | X | X |
| T315I | X | X | X | ||
| FGFR | X | X | X | ||
| VEGFR | X | X | |||
| PDGFR | X | X | X | X | X |
| KIT | X | X | X | X | |
| FLT3 | X | X | X | ||
| SRC | X | X | X |
Note: Over 50% inhibition is indicated by X.
Abbreviations: ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; TKIs, tyrosine kinase inhibitors; ABL1, abelson murine leukemia viral oncogene homolog 1; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; KIT, stem cell growth factor receptor; FLT3, fms-like tyrosine kinase 3; SRC, sarcoma kinase.